EHI
PTGX icon

Eagle Health Investments’s Protagonist Therapeutics PTGX Stock Holding History

Eagle Health Investments’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.4M Buy
248,322
+69,000
+38% +$7.21M 5.05% 8
2026
Q1 		$18.9M Buy
179,322
+122,022
+213% +$10.8M 3.31% 13
2025
Q4 		$5M Buy
+57,300
New +$4.69M 1.1% 21

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Eagle Health Investments's PTGX Position: Q2 2026 in Review

Eagle Health Investments increased its Protagonist Therapeutics (PTGX) stake by 38% in Q2 2026, buying an estimated $7.21M and bringing the position to 248,322 shares worth $30.4M. The position accounts for 5.05% of the portfolio, ranked #8.

Eagle Health Investments first reported a position in PTGX in Q4 2025 and has held it in 3 quarters since. 143 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Eagle Health Investments held 248,322 shares of Protagonist Therapeutics worth $30.4M as of Q2 2026.
  • Eagle Health Investments bought 69,000 Protagonist Therapeutics shares in Q2 2026, an estimated $7.21M.
  • Protagonist Therapeutics made up 5.05% of Eagle Health Investments's portfolio in Q2 2026, its #8 holding.
  • Eagle Health Investments first reported a position in Protagonist Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 143 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Eagle Health Investments's 13F filing for Q2 2026, filed 10 Aug 2026.